Adicet Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Adicet Bio, Inc. on June 11, 2025. The filing details the voting outcomes for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Class I Directors): Stockholders elected Chen Schor and Katie Peng for three-year terms ending in 2028.
- Chen Schor: 32,378,740 votes for; 7,565,794 votes withheld.
- Katie Peng: 32,959,183 votes for; 6,985,351 votes withheld.
- Proposal 2 (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation.
- Votes For: 31,207,255
- Votes Against: 8,621,676
- Abstain: 115,603
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 58,526,922
- Votes Against: 31,442
- Abstain: 290,851
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Confirmation of the new board composition with Chen Schor and Katie Peng serving until 2028.
- Shareholder sentiment on executive compensation, noting a significant number of votes against the proposal (approx. 21.6% of votes cast).
- Confirmation of KPMG LLP as the auditor for the 2025 fiscal year.
- Review of the definitive proxy statement (Schedule 14A) filed on April 29, 2025, for detailed context on the proposals.